Clinical Trial Update: Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC [Phase 2]

View source ↗

Summary

This entry reports a Phase 2 clinical trial evaluating AC0010 for EGFR T790M–positive metastatic non-small cell lung cancer; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AC0010

Snippet

Sponsor: Hangzhou ACEA Pharmaceutical Research Co., Ltd. | Conditions: Metastatic Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN